Stock MRK MERCK & CO., INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Real-time Estimate Cboe BZX
Other stock markets
 02:08:12 2024-04-25 pm EDT 		5-day change 1st Jan Change
130.8 USD +3.00% Intraday chart for Merck & Co., Inc. +4.72% +20.29%
07:01pm Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating MT
06:54pm Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Cantor Fitzgerald Adjusts Merck & Co.' Price Target to $155 From $135, Keeps Overweight Rating
MT
Top Midday Stories: Shares of Meta, IBM, Caterpillar, Comcast and Southwest Down Big Post-Earnings; AstraZeneca Shares See Post-Earnings Bump
MT
Global markets live: Ford, Dow, American Airlines, Comcast, Apple, IBM, Cisco...
Our Logo
The specter of stagflation rears its ugly head again
Our Logo
Merck Lifts Full-Year 2024 Outlook Following First-Quarter Beat
MT
Merck raises annual target ranges
CF
Merck Non-GAAP Earnings, Sales Rise; 2024 Guidance Raised
MT
(MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65
MT
Earnings Flash (MRK) MERCK & CO. Reports Q1 Revenue $15.78B
MT
Earnings Flash (MRK) MERCK & CO. Posts Q1 EPS $2.07
MT
Merck: Q1 Earnings Snapshot
AQ
Merck Announces First-Quarter 2024 Financial Results
BU
Merck & Co., Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Merck & Co., Inc. Provides Earnings Guidance for Full-Year 2024
CI
Merck raises 2024 profit forecast on strong cancer, HPV drugs sales
RE
Scholz promises support for pharma sector in Germany as Merck invests
RE
Hipgnosis' bidding war intensifies as Concord hikes offer for Shakira music owner
RE
Hanmi Pharmaceutical Enters into Clinical Trial Collaboration and Supply Agreement with Merck & Co., Inc. to Evaluate BH3120 in Combination with KEYTRUDA®? (pembrolizumab)
CI
Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer
MT
BMO Capital Adjusts Price Target on Merck & Company to $148 From $132
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. MRK Stock
  4. News Merck & Co., Inc.